66% of the management team is White. Haemonetics Corporation (NYSE:NYSE:HAE) Q4 2022 Results Conference Call May 10, 2022 08:00 AM ET Company Participants Olga Guyette - Director, IR and Treasury Chris Simon - CEO James. Christopher Simon . Executive Vice President . The shares were sold at an average price of $56.10, for a total value of $46,675.20. For its 2021 fiscal year, HAEMONETICS CORP, listed the following CEO pay ratio data on its annual proxy statement to the SEC. He succeeds William Burke . "He has directed strategic financial initiatives enabling us to best . forward to advancing the strategic plan developed with the Haemonetics leadership team and Board of Directors to drive Haemonetics towards a bright future." Simon has . Simon argued the takeover "catalyzes [Haemonetics'] transition from turnaround to transformational growth" by moving it into fast-growing markets adjacent to its existing business. Equity. . He will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. Products. Haemonetics Appoints James D'Arecca Chief Financial Officer. "The NexSys PCS system has transformed and improved the way our customers can collect plasma," said Chris Simon, Haemonetics' President and CEO. Their strong leadership empowers our employees to make it matter for those who depend on us. Haemonetics has signed a lease through 2032 for the 62,000 square feet. "The NexSys PCS system has transformed and improved the way our customers can collect plasma," said Chris Simon, Haemonetics' President and CEO. Chris Simon, Haemonetics' CEO, stated: "Our first quarter performance is a positive start to the year, supported by recovery across all of our businesses, especially Hospital, and the initial Plasma Persona ® rollouts. Haemonetics is a blood management firm that offers devices, software and consulting services for the blood supply chain. Chris Simon, Haemonetics' President and CEO, said, "We are excited to add Cardiva's vascular closure technology to our portfolio and look forward to welcoming their talented team. Publications. HAE ROC % as of today (May 22, 2022) is 3.24%. BOSTON, March 30, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that it has appointed Anila Lingamneni Executive Vice President and Chief Technology Officer, effective April 1, 2020. At Haemonetics, our dedicated leaders work to advance our Mission to improve the quality, effectiveness and efficiency of care. "This divestiture and the recent sale of our U.S. blood donor software help shift our portfolio toward our growth segments," said Chris Simon, Haemonetics' President and CEO. Chris Simon, Haemonetics' President and CEO, said, "We are excited to add Cardiva's vascular closure technology to our portfolio and look forward to welcoming their talented team. This acquisition immediately expands and diversifies our hospital offerings in the large and growing interventional cardiology and electrophysiology markets and . . "Our new downtown location in close proximity to the medical, technology and higher education communities that are driving the future of our industry will help foster innovation and collaboration to improve the quality of care for the patients, donors . Haemonetics (NYSE: HAE) makes blood management devices and software. Field Ride with Chris Simon, CEO of Haemonetics Show more Show less Flight Nurse, RN, BSN AeroCare Medical Transport Oct 2012 - Sep 2014 2 years. Careers Overview. Donors Make It Matter. communities where we live and work," said Chris Simon, President and CEO of Haemonetics. Haemonetics has 3,216 employees, of which 29 are in a leadership position. HAE traded up $1.91 during trading . BOSTON, March 21, 2022 -- Haemonetics Corporation (NYSE: HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022. Haemonetics Announces VASCADE MVP® Venous Vascular Closure System Gains the First and Only FDA Approval for Same-Day Discharge Following Atrial Fibrillation Ablation. He last played for Metallurg Novokuznetsk of the KHL. Carla Burigatto, a company spokeswoman, said Haemonetics officials wanted to be close to public transportation. Chris Simon. Posts Featuring Chris Simon. HAEMONETICS CORP income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Corporate Responsibility at Haemonetics. BOSTON, March 21, 2022 /PRNewswire/ — Haemonetics Company (NYSE: HAE) in the present day introduced that James C. D'Arecca will be a part of the Firm as Govt Vice President, Chief Monetary Officer, efficient April 11, 2022.He'll report on to Chris Simon, Haemonetics' President and Chief Govt Officer.. On this position, D'Arecca will oversee the Firm's treasury, controllership and . Mr. Simon owns over 1,200 units of Haemonetics stock worth over $9,797,450 and over the last 6 years he sold HAE stock worth over $21,971,407. said Chris Simon, chief executive of . the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022. He discusses . $999,509. Chris Simon has been the CEO of Haemonetics Corporation since 2016. "Software that supports our growth and sector leadership remain an important part our Innovation Agenda." Resources. "We have a long-standing relationship with CSL and while we are disappointed by this decision we appreciate the advance notice," said Chris Simon, Haemonetics' President and CEO."We have taken a . scottsdale, az . The estimated Net Worth of Christopher Simon, is at least $41.2 Million dollars as of 14 June 2021. Aug. 25, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO . Haemonetics is committing to more than $100,000 in financial assistance to support COVID-19 . Open Positions. Donors Make It Matter Campaign. In this role, D'Arecca will oversee the Company's treasury, controllership and accounting, investor relations, tax . Solutions. In this role, D'Arecca will oversee the Company's treasury, controllership and accounting, investor . Haemonetics president and CEO Chris Simon said: "We are excited to add Cardiva's vascular closure technology to our portfolio and look forward to welcoming their talented team. In addition, he makes $9,398,200 as President, Chief Executive Officer, and Director at Haemonetics. CHRISTOPHER SIMON President and Chief Executive Officer More. In the News. "Persona builds on that legacy by delivering . Our data indicates that Haemonetics Corporation has a market capitalization of US$3.1b, and total annual CEO compensation was reported as US$8.6m for the year to April 2021. He will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. Haemonetics Announces VASCADE MVP® Venous Vascular Closure System Gains the First and Only FDA Approval for Same-Day Discharge Following Atrial Fibrillation Ablation. Get Contact Info for All Departments Christopher Simon. He will report directly to president and CEO Chris Simon. Mr. Christopher A. Simon is a President, Chief Executive Officer & Director at Haemonetics Corp. Posts Featuring Chris Simon. Calendar of Events. Based on our data team's research, Christopher A. Simon is the Haemonetics's CEO. Chrome Extension. Haemonetics Corporation (NYSE: HAE) ("Haemonetics" or the "Company"), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today . Join to Connect . Scouring the web at all hours of the night wasn't gonna cut it. "Relocating our headquarters to Boston is an important step in Haemonetics' transformation," said Chris Simon, President and CEO of Haemonetics. CEO Pay Ratio. Related Hubs. May 9 (Reuters) - Haemonetics Corp * Haemonetics corporation announces Christopher Simon as president and chief executive officer * Chris currently serves as a senior partner of Mckinsey & Company . "The NexSys PCS system has transformed and improved the way our customers can collect plasma," said Chris Simon, Haemonetics' President and CEO. View Chris Simon's profile on LinkedIn, the world's largest professional community. We took meaningful steps to position the Company for growth, . Haemonetics President and Chief Executive Officer May 2016. We remain confident in the strong end-market demand for our products and continue to anticipate full recovery from the . Mr. Burke joined Haemonetics (HAE) as Chief Financial Officer in August 2016 after spending more than 20 years in finance and business leadership roles at leading healthcare companies, including Medtronic plc, Covidien plc and Tyco Healthcare."Bill was my first hire at Haemonetics (HAE) and has been the co-architect of our turnaround," said Chris Simon, Haemonetics' (HAE) CEO. . Here are further demographic highlights of the leadership team: The Haemonetics executive team is 31% female and 66% male. $1,844,837. BNP Paribas Asset Management Head of Multi-Assets Quant Solutions, APAC Paul Sandhu says traditional cyclicals are clawing their way back and that he is rotating buying opportunities. Haemonetics employs 2,708 employees. This acquisition immediately expands and diversifies our hospital offerings in the large and growing interventional cardiology and electrophysiology markets and . How Does Total Compensation For Chris Simon Compare With Other Companies In The Industry? From Seeking Alpha: Haemonetics Corporation's CEO Chris Simon on Q2 2022 Results -- Earnings Call Transcript https://seekingalpha.com/article/4467352-haemonetic. The shares were sold at an average price of $56.10, for a total value of $46,675.20. So what. Chris Simon, Haemonetics' President and CEO, said, "We are excited to add Cardiva's vascular closure technology to our portfolio and look forward to welcoming their talented team. Chris Simon is President/CEO at Haemonetics Corp. See Chris Simon's compensation, career history, education, & memberships. Health care company Haemonetics Corp. said Wednesday it has agreed to acquire a California-based medical-device company for $475 million in cash upfront. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Haemonetics' NexSys PCS® with Persona™ technology customizes plasma collection based on an individual donor's body composition. Chris will succeed Ronald . According to Haemonetics, the deal could bring in revenues between $65-$75m in the first fiscal year. . Resources. This acquisition immediately expands and diversifies our hospital offerings in the large and growing interventional cardiology and electrophysiology markets and . She will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. Haemonetics is paying $475 million and committing to up to $35 million based on sales growth. Start Free Trial . President and Chief Executive Officer. . The new, proprietary Persona technology is the latest innovation… Haemonetics (NYSE:HAE) this week appointed James D'Arecca as chief financial officer, effective on April 11. . . Christopher Simon is the President and Chief Executive Officer at Haemonetics. Search Crunchbase. "We are confident that GVS . President and Chief Executive Officer at Haemonetics Greater Boston 500+ connections. I'd like to turn it over to Chris. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected] Learn More on Christopher Simon's contact information. BOSTON, March 21, 2022 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022.He will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer.. Plasma collections improved and we continued to convert customers to our latest NexSys and Persona technologies, while our Hospital . "We are committed to doing our part to respond to the COVID-19 pandemic by not only supporting our Going in the opposite direction, but not alarmingly so . MICHELLE L. BASIL Executive Vice President, General Counsel . In depth view into Haemonetics ROC % explanation, calculation, historical data and more . Chris Simon, Haemonetics' President and CEO, said, "We are excited to add Cardiva's vascular closure technology to our portfolio and look forward to welcoming their talented team. Our workflow has solid direction now - we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering. "Bill was my first hire at Haemonetics and has been the co-architect of our turnaround," said Chris Simon, Haemonetics' CEO. Executive Summary. News & Events. Chris Simon, Haemonetics' CEO, stated: "The pandemic affected fiscal 2021, particularly our Plasma business, but cost mitigation efforts coupled with the Operational Excellence Program helped dampen the impact. . BOSTON, July 24, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its wholly-owned subsidiary Inlog Holdings France SAS to Abénex.Abénex is a fully independent private equity firm based in . In the fifth year, it could deliver a 10% rate of return on . Haemonetics Corporation (HAE) CEO Chris Simon on Q4 2022 Results - Earnings Call Transcript Haemonetics Corporation (NYSE:NYSE:HAE) Q4 2022 . Chris Simon. This acquisition immediately expands and diversifies our hospital offerings in the large and growing interventional cardiology and electrophysiology markets and . HAE traded up $1.91 during trading . Learn More. Haemonetics Corporation (NYSE:NYSE:HAE) Q2 2022 Earnings Conference Call November 09, 2021, 08:00 AM ET Company Participants Olga Guyette - Director, Investor Relations Chris Simon -. On Monday, May 16th, Christopher Simon sold 832 shares of Haemonetics stock. Our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. 10 stocks we like better than Haemonetics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Investors may take more convincing. Cardiva is central to that next phase. "Persona builds on that legacy by delivering . BOSTON, March 21, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022.He will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. GuruFocus Article or News written by PRNewswire and the topic is about: to pursue operational excellence to offer our customers high quality products through an asset-lite approach," said Chris Simon, Haemonetics' President and CEO. Christopher Simon - President and Chief Executive Officer @ Haemonetics. Haemonetics Corporation (NYSE: HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022.He will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. Welcome to the Haemonetics First Quarter Fiscal 2022 Conference Call and Webcast. He will report directly to Chris Simon, Haemonetics' President and Chief . HAE. $33,403. Chris Simon-- Chief Executive Officer. We had no where to begin. . Total Compensation. Careers. Haemonetics booked revenue of $240 million for its second quarter of fiscal 2022, which was 15% higher on a year-over-year basis. GuruFocus Article or News written by PRNewswire and the topic is about: Mr. Simon was previously employed as a Senior Partner by McKinsey & Co., Inc. Haemonetics Appoints James D'Arecca Chief Financial Officer. Find related and similar companies as well as employees by title and much more. View Haemonetics (www.haemonetics.com) location in Massachusetts, United States , revenue, industry and description. In this role, D'Arecca will oversee the Company's treasury, controllership and . RocketReach has given us a great place to start. Other. He is on the Board of Directors at Haemonetics Corp. and Advanced Medical Technology Association. In an interview, CEO Chris Simon said relocating to Boston is an important step in the company's transformation, . Haemonetics's Profile, Revenue and Employees. The corporate mailing address for Mr. Simon and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. On Monday, May 16th, Christopher Simon sold 832 shares of Haemonetics stock. The Haemonetics management team includes Chris Simon (President and Chief Executive Officer), Bill Burke (Chief Financial Officer), and Anila Lingamneni (Executive Vice President, Chief Technology Officer). Christopher J. Simon (born January 30, 1972) is a Canadian former professional ice hockey left winger, who played 20 seasons of ice hockey: 15 seasons in the NHL and 5 seasons in the Kontinental Hockey League. Edit Related Hubs . On June 3rd 2020 GVS S.p.A. signed an agreement to acquire Haemonetics' plant in Fajardo and to supply and develop blood filters for Haemonetics . President & CEO of Haemonetics Corp ( 30-Year Financial, Insider Trades) Christopher Simon, ( insider trades) sold 50,869 shares of HAE on 08/19/2019 at an average price of $137.43 a share . Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its NexSys PCS® system with Persona™ technology. BOSTON, March 21, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022.He will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. From Seeking Alpha: Haemonetics Corporation's CEO Chris Simon on Q2 2022 Results -- Earnings Call Transcript https://seekingalpha.com/article/4467352-haemonetic. The Braintree, Mass.-based blood management company also said it named Chris Simon to be its new CEO, replacing interim chief Ron Gelbman, who took the reins after the September 2015 departure of . At this time, all participants are in a listen-only mode. . View our latest analysis for Haemonetics . Haemonetics is THE Blood Management Company. . Boston-based medical device company Haemonetics Corp. has entered into a definitive agreement to acquire a California-based vascular device company for up to $510 million. Chris Simon, Haemonetics' CEO, stated: "Our third-quarter results reflect our agility and resilience in meeting the challenges of the pandemic on U.S. blood and plasma collections and some hospital products. Michelle L. Basil. CEO Name. HAEMONETICS CORP annual reports of executive compensation and pay are most commonly found in the Def 14a documents.